Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 41

1.

Mutant Calreticulin Requires Both Its Mutant C-terminus and the Thrombopoietin Receptor for Oncogenic Transformation.

Elf S, Abdelfattah NS, Chen E, Perales-Patón J, Rosen EA, Ko A, Peisker F, Florescu N, Giannini S, Wolach O, Morgan EA, Tothova Z, Losman JA, Schneider RK, Al-Shahrour F, Mullally A.

Cancer Discov. 2016 Apr;6(4):368-81. doi: 10.1158/2159-8290.CD-15-1434. Epub 2016 Mar 7.

PMID:
26951227
2.

RECQL5 Suppresses Oncogenic JAK2-Induced Replication Stress and Genomic Instability.

Chen E, Ahn JS, Sykes DB, Breyfogle LJ, Godfrey AL, Nangalia J, Ko A, DeAngelo DJ, Green AR, Mullally A.

Cell Rep. 2015 Dec 22;13(11):2345-52. doi: 10.1016/j.celrep.2015.11.037. Epub 2015 Dec 10.

3.

Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition.

Wen QJ, Yang Q, Goldenson B, Malinge S, Lasho T, Schneider RK, Breyfogle LJ, Schultz R, Gilles L, Koppikar P, Abdel-Wahab O, Pardanani A, Stein B, Gurbuxani S, Mullally A, Levine RL, Tefferi A, Crispino JD.

Nat Med. 2015 Dec;21(12):1473-80. doi: 10.1038/nm.3995. Epub 2015 Nov 16.

4.

Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years.

Schram AM, Comstock P, Campo M, Gorovets D, Mullally A, Bodio K, Arnason J, Berliner N.

Br J Haematol. 2016 Feb;172(3):412-9. doi: 10.1111/bjh.13837. Epub 2015 Nov 5.

PMID:
26537747
5.

How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?

Chen E, Mullally A.

Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):268-76. doi: 10.1182/asheducation-2014.1.268. Epub 2014 Nov 18. Review.

PMID:
25696866
6.

Marked hyperferritinemia does not predict for HLH in the adult population.

Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E, Neuberg D, Berliner N.

Blood. 2015 Mar 5;125(10):1548-52. doi: 10.1182/blood-2014-10-602607. Epub 2015 Jan 8.

7.

Role of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology.

Ishikawa Y, Maeda M, Pasham M, Aguet F, Tacheva-Grigorova SK, Masuda T, Yi H, Lee SU, Xu J, Teruya-Feldstein J, Ericsson M, Mullally A, Heuser J, Kirchhausen T, Maeda T.

Haematologica. 2015 Apr;100(4):439-51. doi: 10.3324/haematol.2014.119537. Epub 2014 Dec 31.

8.

Dynamin 2-dependent endocytosis is required for normal megakaryocyte development in mice.

Bender M, Giannini S, Grozovsky R, Jönsson T, Christensen H, Pluthero FG, Ko A, Mullally A, Kahr WH, Hoffmeister KM, Falet H.

Blood. 2015 Feb 5;125(6):1014-24. doi: 10.1182/blood-2014-07-587857. Epub 2014 Dec 2.

9.

Hit the spleen, JAK!

Lane SW, Mullally A.

Blood. 2014 Nov 6;124(19):2898-900. doi: 10.1182/blood-2014-09-600635.

10.

JAK2V617F promotes replication fork stalling with disease-restricted impairment of the intra-S checkpoint response.

Chen E, Ahn JS, Massie CE, Clynes D, Godfrey AL, Li J, Park HJ, Nangalia J, Silber Y, Mullally A, Gibbons RJ, Green AR.

Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15190-5. doi: 10.1073/pnas.1401873111. Epub 2014 Oct 6.

11.

Distinct effects of concomitant Jak2V617F expression and Tet2 loss in mice promote disease progression in myeloproliferative neoplasms.

Chen E, Schneider RK, Breyfogle LJ, Rosen EA, Poveromo L, Elf S, Ko A, Brumme K, Levine R, Ebert BL, Mullally A.

Blood. 2015 Jan 8;125(2):327-35. doi: 10.1182/blood-2014-04-567024. Epub 2014 Oct 3.

12.

Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS.

Schneider RK, Ademà V, Heckl D, Järås M, Mallo M, Lord AM, Chu LP, McConkey ME, Kramann R, Mullally A, Bejar R, Solé F, Ebert BL.

Cancer Cell. 2014 Oct 13;26(4):509-20. doi: 10.1016/j.ccr.2014.08.001. Epub 2014 Sep 18.

13.

Loss of function of TET2 cooperates with constitutively active KIT in murine and human models of mastocytosis.

De Vita S, Schneider RK, Garcia M, Wood J, Gavillet M, Ebert BL, Gerbaulet A, Roers A, Levine RL, Mullally A, Williams DA.

PLoS One. 2014 May 2;9(5):e96209. doi: 10.1371/journal.pone.0096209. eCollection 2014.

14.

Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia.

Järås M, Miller PG, Chu LP, Puram RV, Fink EC, Schneider RK, Al-Shahrour F, Peña P, Breyfogle LJ, Hartwell KA, McConkey ME, Cowley GS, Root DE, Kharas MG, Mullally A, Ebert BL.

J Exp Med. 2014 Apr 7;211(4):605-12. doi: 10.1084/jem.20131033. Epub 2014 Mar 10.

15.

A prospective cohort study of alcohol exposure in early and late pregnancy within an urban population in Ireland.

Murphy DJ, Dunney C, Mullally A, Adnan N, Fahey T, Barry J.

Int J Environ Res Public Health. 2014 Feb 17;11(2):2049-63. doi: 10.3390/ijerph110202049.

16.

Sinister symbiosis: pathological hematopoietic-stromal interactions in CML.

Mullally A, Ebert BL.

Cell Stem Cell. 2013 Sep 5;13(3):257-8. doi: 10.1016/j.stem.2013.08.009.

17.

Population-based study of smoking behaviour throughout pregnancy and adverse perinatal outcomes.

Murphy DJ, Dunney C, Mullally A, Adnan N, Deane R.

Int J Environ Res Public Health. 2013 Aug 27;10(9):3855-67. doi: 10.3390/ijerph10093855.

18.

Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.

Mullally A, Bruedigam C, Poveromo L, Heidel FH, Purdon A, Vu T, Austin R, Heckl D, Breyfogle LJ, Kuhn CP, Kalaitzidis D, Armstrong SA, Williams DA, Hill GR, Ebert BL, Lane SW.

Blood. 2013 May 2;121(18):3692-702. doi: 10.1182/blood-2012-05-432989. Epub 2013 Mar 13.

19.

Behavioural change in relation to alcohol exposure in early pregnancy and impact on perinatal outcomes--a prospective cohort study.

Murphy DJ, Mullally A, Cleary BJ, Fahey T, Barry J.

BMC Pregnancy Childbirth. 2013 Jan 16;13:8. doi: 10.1186/1471-2393-13-8.

20.

Myeloproliferative neoplasm animal models.

Mullally A, Lane SW, Brumme K, Ebert BL.

Hematol Oncol Clin North Am. 2012 Oct;26(5):1065-81. doi: 10.1016/j.hoc.2012.07.007. Epub 2012 Aug 21. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk